공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

동질접합 가족성 고콜레스테롤혈증(HoFH) : 파이프라인 리뷰

Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H2 2019

리서치사 Global Markets Direct
발행일 2019년 12월 상품 코드 361615
페이지 정보 영문 118 Pages
가격
US $ 2,000 ₩ 2,221,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,442,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,663,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


동질접합 가족성 고콜레스테롤혈증(HoFH) : 파이프라인 리뷰 Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H2 2019
발행일 : 2019년 12월 페이지 정보 : 영문 118 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

동질접합 가족성 고콜레스테롤혈증(HoFH)은 부모로부터의 돌연변이에 의해 발생하는 유전성 질환으로, LDL 콜레스테롤치가 매우 높아집니다. 증상은 황색판종, 흉통, (뒤꿈치가 아닌) 발끝 통증 등입니다. 치료법은 식생활의 변경, 스타틴계 약제 등입니다.

동질접합 가족성 고콜레스테롤혈증(HoFH) 치료제의 개발 상황에 대해 조사분석했으며, 파이프라인 제품의 개요, 임상시험 단계별 제품의 개요, 주요 기업의 개요, 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등에 관한 정보를 정리하여 전해드립니다.

서론

  • 조사 범위

동질접합 가족성 고콜레스테롤혈증(HoFH) 개요

치료제 개발

  • 파이프라인 제품의 개요
  • 기업별 파이프라인
  • 기업에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

동질접합 가족성 고콜레스테롤혈증(HoFH) 치료제 개발에 참여하고 있는 기업

  • CymaBay Therapeutics Inc
  • Daewoong Co Ltd
  • Gemphire Therapeutics Inc
  • LipimetiX Development Inc
  • Regeneron Pharmaceuticals Inc
  • RegenxBio Inc
  • The Medicines Company

약제 개요

휴지중인 프로젝트

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

KSA 17.08.23

List of Tables

  • Number of Products under Development for Homozygous Familial Hypercholesterolemia (HoFH), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline by AD Pharmaceuticals Co Ltd, H2 2019
  • Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline by Amryt Pharma Plc, H2 2019
  • Homozygous Familial Hypercholesterolemia (HoFH) - Dormant Projects, H2 2019
  • Homozygous Familial Hypercholesterolemia (HoFH) - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Homozygous Familial Hypercholesterolemia (HoFH), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H2 2019, provides an overview of the Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) pipeline landscape.

Homozygous familial hypercholesterolemia is a genetic disorder which is caused due to mutation from both parents. HoFH causes LDL cholesterol level to be very high. Symptoms include xanthelasmas, chest pain and sores on the toes that do not heal. Treatment includes diet changes and statin drugs.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Homozygous Familial Hypercholesterolemia (HoFH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 4, 5, 2, 4 and 1 respectively.

Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Homozygous Familial Hypercholesterolemia (HoFH) - Overview
    • Homozygous Familial Hypercholesterolemia (HoFH) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Homozygous Familial Hypercholesterolemia (HoFH) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Homozygous Familial Hypercholesterolemia (HoFH) - Companies Involved in Therapeutics Development
    • AD Pharmaceuticals Co Ltd
    • Amryt Pharma Plc
    • Beijing Mabworks Biotech Co Ltd
    • Daewoong Co Ltd
    • Gemphire Therapeutics Inc
    • Innovent Biologics Inc
    • LIB Therapeutics LLC
    • Lipigon Pharmaceuticals AB
    • LipimetiX Development Inc
    • Madrigal Pharmaceuticals Inc
    • Pfizer Inc
    • Regeneron Pharmaceuticals Inc
    • RegenxBio Inc
    • The Medicines Company
  • Homozygous Familial Hypercholesterolemia (HoFH) - Drug Profiles
  • Homozygous Familial Hypercholesterolemia (HoFH) - Dormant Projects
  • Homozygous Familial Hypercholesterolemia (HoFH) - Discontinued Products
  • Homozygous Familial Hypercholesterolemia (HoFH) - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q